Okay, lets see how the panel will discuss these points:
Point 1-3: patients from 001 trial used the same lot of cells. thus, there is little variability of TNFR1 expression in the same lot of cells. the outcome (ie: responder vs non-responder) might be purely attributed to variability in patients and their immune system and disease severity/stage.
Point 4: Significant was observed (as shown by SI) the optimized protocol produced better outcome. But importantly, TNFR1 expression level correlates with survival/better outcome.
Okay, lets see how the panel will discuss these points:Point...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.02 |
Change
0.085(9.14%) |
Mkt cap ! $1.141B | |||
| Open | High | Low | Value | Volume |
| 95.0¢ | $1.02 | 94.0¢ | $9.138M | 9.255M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 62069 | $1.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.02 | 110095 | 12 |
View Market Depth
| Last trade - 12.27pm 29/04/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.03 |
Change
0.085 ( 11.4 %) |
||||
| Open | High | Low | Volume | ||
| 94.0¢ | $1.03 | 94.0¢ | 1909783 | ||
| Last updated 12.47pm 29/04/2024 ? | |||||
| MSB (ASX) Chart |